Nathan J. Pauly

Nathan Pauly is a senior manager with Manatt Health, an interdisciplinary policy and business advisory practice of Manatt. He provides quantitative and qualitative research support and strategic advice on health care business and policy issues.

Before joining Manatt, Nathan worked as the director of Medicaid research and evaluation at the West Virginia University (WVU) Office of Health Affairs, where he conducted program evaluations and data analyses for the West Virginia Bureau for Medical Services. While at WVU, Nathan led an evaluation of the West Virginia Medicaid agency’s Diabetes Health Home Program and assisted with an evaluation of the state’s 1115 Substance Use Disorder Waiver, among other projects. He also led a team of WVU data analysts embedded within the Bureau for Medical Services to analyze Medicaid claims data and provide research and decision support to West Virginia Medicaid leadership.

Nathan completed a Ph.D. in pharmaceutical sciences with the Institute for Pharmaceutical Outcomes and Policy at the University of Kentucky College of Pharmacy. His graduate research focused on low-cost generic drug discount programs as well as policy responses to the opioid epidemic.

Senior Manager

Nathan J. Pauly

Chicago

312.477.4788

Download vCard

Services

Manatt Health

Offices

Chicago

On This Page

Bio

Nathan J. Pauly

Nathan Pauly is a senior manager with Manatt Health, an interdisciplinary policy and business advisory practice of Manatt. He provides quantitative and qualitative research support and strategic advice on health care business and policy issues.

Before joining Manatt, Nathan worked as the director of Medicaid research and evaluation at the West Virginia University (WVU) Office of Health Affairs, where he conducted program evaluations and data analyses for the West Virginia Bureau for Medical Services. While at WVU, Nathan led an evaluation of the West Virginia Medicaid agency’s Diabetes Health Home Program and assisted with an evaluation of the state’s 1115 Substance Use Disorder Waiver, among other projects. He also led a team of WVU data analysts embedded within the Bureau for Medical Services to analyze Medicaid claims data and provide research and decision support to West Virginia Medicaid leadership.

Nathan completed a Ph.D. in pharmaceutical sciences with the Institute for Pharmaceutical Outcomes and Policy at the University of Kentucky College of Pharmacy. His graduate research focused on low-cost generic drug discount programs as well as policy responses to the opioid epidemic.

Education

University of Kentucky College of Pharmacy, Ph.D., Pharmaceutical Sciences, 2018

Vanderbilt University, B.A., Medicine, Health and Society, 2014

Accomplishments

Speaker, “An Evaluation of WV Medicaid’s Response to the COVID-19 Pandemic: Planning Phase,” State University Partnership Learning Network Annual Meeting, December 8–10, 2020.

Speaker, “Medicaid Outcomes Distributed Research Network (MODRN) OUD Project: Findings and Future Opportunities,” State University Partnership Learning Network Annual Meeting, December 12–13, 2019.

Speaker, “The Impact of Prescription Drug Monitoring Program Characteristics on Rates of Opioid-Related Poisonings,” International Society for Pharmacoepidemiology Mid-Year Meeting, April 1-4, 2017.

Most-cited manuscript in the Journal of Managed Care and Specialty Pharmacy, for “Trends in Gabapentin Use in a Commercially-Insured US Adult Population, 2009–2016,” 2020

November Research Highlight of the Month, University of Kentucky College of Pharmacy, for paper “Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic,” 2016

First-place graduate student poster in clinical sciences, Markey Cancer Center Annual Research Day, 2016

Gold medal abstract, Academy of Managed Care Pharmacy Annual Meeting, 2016

Honorable Mention for Best Graduate Student Poster, Academy of Managed Care Pharmacy Annual Meeting, 2016

Co-author, “Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B,” Journal of Managed Care & Specialty Pharmacy, June 26, 2024.

Co-author, “Do Health Care Providers That Serve Historically Marginalized Populations Get Paid Less?,” Arnold Ventures, July 2024.

Co-author, “Remote Physiologic Monitoring Use Among Medicaid Population Increased, 2019–21,” Health Affairs, May 2024.

Co-author, “Leveraging Health Care Cost and Affordability Data: A Suite of Analytic Resources,” the Peterson-Milbank Program for Sustainable Health Care Costs, November 2, 2023.

Co-author, “Assessing Geographic Variation in Rates of Cervical Cancer and Recurrent or Metastatic Cervical Cancer Among Medicaid Enrollees,” American Journal of Clinical Oncology, September 2023.

Co-author, “Implementing State-Level Policy and Operational Processes That Enhance Access to Medicaid Family Planning Program Services,” with support from Arnold Ventures, June 2023.

Co-author, “Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak — West Virginia, 2018–2019,” Morbidity and Mortality Weekly Report, February 2021.

Co-author, “Healthcare Patterns of Pregnant Women and Children Affected by OUD in 9 State Medicaid Populations,” Journal of Addiction Medicine, Epub, February 2021.

Co-author, “Trends in Gabapentin Use in a Commercially-Insured US Adult Population 2009–2016,” Journal of Managed Care & Specialty Pharmacy, 2020.

Co-author, “Innovative Solutions for State Medicaid Programs to Leverage Their Data, Build Capacity, and Create Evidence-Based Policy,” Generating Evidence & Methods to Improve Patient Outcomes (eGEMS), August 2019.

Co-author, “Kentucky’s Smoking Cessation Quitline: Annual Estimated Return on Investment to Employers,” American Journal of Health Promotion, February 2019.

Co-author, “Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings,” Drug and Alcohol Dependence, March 2018.

Related Practices

Industries

Manatt Health

Join our newsletter to stay up to date on features and releases.

ATTORNEY ADVERTISING, pursuant to New York DR 2-101(f)

© 2025 Manatt, Phelps & Phillips, LLP. All rights reserved.

Newsletter Subscription